Loading
A phase 2 trial of iparomlimab and tuvonralimab in lung cancer, run by Guangdong Association of Clinical Trials, not yet recruiting.
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC is a phase 2, interventional study registered as NCT07416058 by Guangdong Association of Clinical Trials, with a registry enrolment figure of 61 participants, started 2026-01-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: QL1706 (bispecific antibody targeting PD-1 and CLTA-4). Conditions listed: Lung Adenocarcinoma. Primary outcome: Objective Response Rate (ORR) per RECIST 1.1. Lung eligibility wording from the registry: "The study will enroll adult patients (aged 18-75 years) with histologically confirmed locally advanced or metastatic NSCLC (AJCC 9th Edition, Stage IIIB-IVB), and harbor confirmed actionable driver mutations for which targeted therapies are available; these mutations are stratified as follows: EGFR ". No results are recorded here; the registry entry is the source.
Shares Adenocarcinoma of the lung, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Iparomlimab and tuvonralimab, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Adenocarcinoma of the lung, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Adenocarcinoma of the lung, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Qilu Pharmaceutical, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Iparomlimab and tuvonralimab, Qilu Pharmaceutical, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.